Skip to search formSkip to main contentSkip to account menu

resminostat

An orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity. Resminostat binds to and inhibits HDACs… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

4SC-201RAS 2410

Broader (2)

Hydroxamic AcidsSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy.
252Background: Resminostat is an oral hydroxamate-type inhibitor of class I, IIB, and IV histone deacetylases. A European Phase… 
2017
2017
Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines
Carcinogenesis is determined by various epigenetic events, such as histone deacetylation. The purpose of this study was to… 
2016
2016
Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
Oncolytic viruses (OV) constitute highly promising innovative biological anticancer agents. However, like every other antitumoral… 
2016
2016
Resminostat: Opening the door to epigenetic treatments for liver cancer
cer antigen 19-9 (CA19-9) value 1000 U/mL (HR 5 2.6, 95% CI 1.7-4.0; P< 0.001), and tumor size (HR 5 1.05/cm, 95% CI 1.01-1.11/cm… 
2015
2015
A phase I study of resminostat in Japanese patients with advanced solid tumors
PurposeThis study was performed to evaluate the safety and determine the recommended dose (RD) of resminostat monotherapy, an… 
2013
2013
Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial.
e15088 Background: Previously published results of the phase I/II SHELTER study demonstrated efficacy and safety of the novel pan… 
Review
2012
Review
2012
Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.
4115 Background: Resminostat (R), an oral HDAC inhibitor, was studied in the SHELTER trial evaluating safety, PK and efficacy in… 
Review
2012
Review
2012
Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study.
262 Background: Resminostat (4SC-201), an oral pan-HDAC inhibitor, is in clinical development in a variety of cancer indications… 
2011
2011
Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma
Abstract 2675 Background: Resminostat is an oral pan-histone deacetylase (HDAC) inhibitor that has shown anti-tumor activity in a… 
2010
2010
Resminostat in relapsed or refractory Hodgkin Lymphoma: Initial results of the SAPHIRE phase II trial with a novel oral histone deacetylase (HDAC) inhibitor
The study has started in Jan 2010 and has completed accrual of the first 18 pts Background Resminostat in Relapsed or Refractory… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)